Cystic fibrosis drug gets PBS listing

About 250 Australians with a rare form of cystic fibrosis will gain access to $300,000-a-year drug ivacaftor (Kalydeco) when it is listed on the PBS from December.

The drug is effective in patients with the G551D mutation, which is about 5% of people with the disease. It deactivates the genetic defect and allows the body to break down and drain mucus in the lungs and digestive system.

Federal Health Minister Peter Dutton